3 Top-Rated Value Stocks To Buy In March

CVS is expected to see revenue growth of 2.4% for the quarter ended March 31, 2021, and 4.2% in 2021. Its  EPS is estimated to grow 8.3% in 2022 and at a rate of 3.8% per annum over the next five years.

CVS’s strong fundamentals are reflected in its POWR Ratings. The stock has an overall rating of B, which equates to Buy in our proprietary ratings system. The POWR Ratings are calculated by considering 118 different factors with each factor weighted to an optimal degree.

It has an A  grade for Value and B for Stability. In the B-rated, 5-stock Medical- Drug Stores industry, it is ranked #1.

In total, we rate CVS on eight different levels. Beyond what we stated above, we have also given CVS grades for Quality, Sentiment, Momentum, and Growth. Get all the CVS ratings here.

Gilead Sciences, Inc. (GILD - Get Rating)

GILD develops researches and markets medical treatments for a variety of health conditions. The company focuses primarily on AIDS, liver diseases, cardiovascular diseases, and respiratory issues. GILD has returned 6.3% over the past three months and closed the last trading session at $63.68.

The company is collaborating with Gritstone Oncology, Inc. to research and develop a vaccine-based cure for HIV/AIDS. It is also pursuing a cure for Chronic Hepatitis B virus in partnership with Vir Biotechnology, Inc.

In terms of forward price/earnings, the stock is currently trading at 8.99x, which is much lower than the industry average  24.58x. The stock is trading at a discount in terms of price/sales also (3.25x vs. 9.90x).

GILD’s revenue is estimated to increase 20.5% for the quarter ended March 31, 2021. The company’s EPS is expected to rise 20.2% for the quarter ended March 31, 2021, and 58.6% for the quarter ended June 30, 2021.

The POWR Ratings are also high on GILD. it has an Overall Rating of A, which translates to a Strong Buy. GILD also has Value and Growth ratings of A along with Momentum and Quality ratings of B. In the 487-stock Biotech industry, it is ranked #2.

View single page >> |

Disclaimer: Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use, please ...

more
How did you like this article? Let us know so we can better customize your reading experience.

Comments

Leave a comment to automatically be entered into our contest to win a free Echo Show.